Gossamer Bio's consensus analyst price target has recently risen from $8.86 to $9.50, which signals a more optimistic outlook among market observers. This adjustment comes as analyst sentiment grows ...

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) just unveiled an update. On November 13, 2025, Eupraxia Pharmaceuticals announced additional 52-week ...

The CEO highlighted results from the REMAIN-1 Midpoint Cohort, where "Revita-treated patients lost an additional 2.5% of total body weight, while patients in the sham group regained about 10%, a ...

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

Digital health is transforming healthcare delivery by integrating advanced information technologies to improve outcomes, ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

Q3 2025 Management View CEO Peter Altman provided updates on regulatory progress for CardiAMP cell therapy targeting ischemic heart failure, noting, "we have been working on regulatory submissions on ...

If successful in the Phase III trial, VK2735 would enter direct competition with established dual agonists such as Eli ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

The plausible mechanism pathway "could accelerate gene therapy/editing development," analysts at William Blair said Thursday, ...